Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients.
basic (laboratory) research / science
flow cytometry
immunobiology
infection and infectious agents - viral: Cytomegalovirus (CMV)
infectious disease
kidney transplantation / nephrology
translational research / science
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
08
06
2021
received:
03
02
2021
accepted:
10
06
2021
pubmed:
22
6
2021
medline:
1
2
2022
entrez:
21
6
2021
Statut:
ppublish
Résumé
Primary infection and/or reactivation of cytomegalovirus (CMV) in kidney transplant recipients (KTR) favor rejection and mortality. T follicular helper cells (TFH) could contribute to protection against CMV. Circulatory TFH (cTFH) were studied pretransplant and early posttransplant in 90 CMV seropositive KTR not receiving antithymocyte globulin or antiviral prophylaxis, followed-up for 1 year. Patients who presented CMV infection had significantly lower cTFH and activated cTFH pretransplant and early posttransplant. Pretransplant activated cTFH were also lower within patients who developed CMV disease. Pre- and 14 days posttransplant activated cTFH were an independent protective factor for CMV infection (HR 0.41, p = .01; and 0.52, p = .02, respectively). KTR with low cTFH 7 days posttransplant (<11.9%) had lower CMV infection-free survival than patients with high cTFH (28.2% vs. 67.6%, p = .002). cTFH were associated with CMV-specific neutralizing antibodies (Nabs). In addition, IL-21 increased interferon-γ secretion by CMV-specific CD8
Identifiants
pubmed: 34153157
doi: 10.1111/ajt.16725
pii: S1600-6135(22)08842-6
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3946-3957Informations de copyright
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015;15(12):3024-3040. https://doi.org/10.1111/ajt.13486
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13512. https://doi.org/10.1111/ctr.13512
Harvala H, Stewart C, Muller K, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85(5):893-898. https://doi.org/10.1002/jmv.23539
Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. CMR. 2009;22(1):76-98. https://doi.org/10.1128/CMR.00034-08
Polić B, Hengel H, Krmpotić A, et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med. 1998;188(6):1047-1054.
Lilleri D, Zelini P, Fornara C, et al. Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients. J Med Virol. 2018;90(10):1620-1628. https://doi.org/10.1002/jmv.25225
Giménez E, Blanco-Lobo P, Muñoz-Cobo B, et al. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. J Gen Virol. 2015;96(9):2822-2831. https://doi.org/10.1099/vir.0.000203
Gabanti E, Bruno F, Lilleri D, et al. Human Cytomegalovirus (HCMV)-Specific CD4+ and CD8+ T Cells Are Both Required for Prevention of HCMV Disease in Seropositive Solid-Organ Transplant Recipients. Spencer J, ed. PLoS One. 2014;9(8):e106044-https://doi.org/10.1371/journal.pone.0106044
Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817-824. https://doi.org/10.1093/cid/cis993
Meesing A, Razonable RR. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. Expert Rev Clin Pharmacol. 2018;11(8):773-788. https://doi.org/10.1080/17512433.2018.1501557
Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48(6):772-786. https://doi.org/10.1086/597089
Fernández-Ruiz M, López-Medrano F, Allende LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transpl Int. 2014;27(7):674-685. https://doi.org/10.1111/tri.12321
Sandonís V, García-Ríos E, McConnell MJ, Pérez-Romero P. Role of neutralizing antibodies in CMV infection: implications for new therapeutic approaches. Trends Microbiol. 2020;28(11):900-912. https://doi.org/10.1016/j.tim.2020.04.003
Blanco-Lobo P, Cordero E, Martín-Gandul C, et al. Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation. J Infect. 2016;72(5):597-607. https://doi.org/10.1016/j.jinf.2016.02.008
Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008;22(1):89-97. https://doi.org/10.1111/j.1399-0012.2007.00750.x
Snydman DR, Kistler KD, Ulsh P, Bergman GE, Vensak J, Morris J. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database. Clin Transplant. 2011;25(4):E455-E462. https://doi.org/10.1111/j.1399-0012.2011.01459.x
Martins JP, Andoniou CE, Fleming P, et al. Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. Science. 2019;363(6424):288-293. https://doi.org/10.1126/science.aat0066
Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. Cxc chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000;192(11):1553-1562. https://doi.org/10.1084/jem.192.11.1553
Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132-1148. https://doi.org/10.1016/j.immuni.2019.04.011
Vinuesa CG, Cook MC. Blood relatives of follicular helper T cells. Immunity. 2011;34(1):10-12. https://doi.org/10.1016/j.immuni.2011.01.006
Schmitt N, Bentebibel S-E, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol. 2014;35(9):436-442. https://doi.org/10.1016/j.it.2014.06.002
Morita R, Schmitt N, Bentebibel S-E, et al. Human blood CXCR5+CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108-121. https://doi.org/10.1016/j.immuni.2010.12.012
de Graav GN, Dieterich M, Hesselink DA, et al. Follicular T helper cells and humoral reactivity in kidney transplant patients. Clin Exp Immunol. 2015;180(2):329-340. https://doi.org/10.1111/cei.12576
Shi W, Dong L, Sun Q, Ding H, Meng J, Dai G. Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. Exp Cell Res. 2018;372(1):35-42. https://doi.org/10.1016/j.yexcr.2018.09.006
Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 2002;16(4):559-569. https://doi.org/10.1016/S1074-7613(02)00295-9
Bentebibel S-E, Lopez S, Obermoser G, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5(176):176ra32. https://doi.org/10.1126/scitranslmed.3005191
Koutsakos M, Wheatley AK, Loh L, et al. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci Transl Med. 2018;10(428):eaan8405. https://doi.org/10.1126/scitranslmed.aan8405
Matsui K, Adelsberger JW, Kemp TJ, Baseler MW, Ledgerwood JE, Pinto LA. Circulating CXCR5+CD4+ T follicular-like helper cell and memory B cell responses to human papillomavirus vaccines. Ho PL, ed. PLoS One. 2015;10(9):e0137195-https://doi.org/10.1371/journal.pone.0137195
Obeng-Adjei N, Portugal S, Tran T, et al. Circulating Th1-Cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute malaria in children. Cell Rep. 2015;13(2):425-439. https://doi.org/10.1016/j.celrep.2015.09.004
Locci M, Havenar-Daughton C, Landais E, et al. Human circulating PD-1+CXCR3−CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39(4):758-769. https://doi.org/10.1016/j.immuni.2013.08.031
Zhang J, Liu W, Wen BO, et al. Circulating CXCR3+ Tfh cells positively correlate with neutralizing antibody responses in HCV-infected patients. Sci Rep. 2019;9(1):10090. https://doi.org/10.1038/s41598-019-46533-w
Loupy A, Haas M, Solez K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28-41. https://doi.org/10.1111/ajt.14107
Haas M. The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant. 2016;16(5):1352-1357. https://doi.org/10.1111/ajt.13661
Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials: table 1. Snydman DR, ed. Clin Infect Dis. 2017;64(1):87-91. https://doi.org/10.1093/cid/ciw668
Cano-Romero FL, Laguna Goya R, Utrero-Rico A, et al. Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients. Am J Transplant. 2019;19(1):89-97. https://doi.org/10.1111/ajt.14987
Oliver B, Jackson E, Soliman H. Chapter 17 - immunostimulators and immunomodulators in cancer treatment. (Singh M, Salnikova M, eds.). Academic Press; 2015. https://doi.org/10.1016/B978-0-12-416603-5.00017-1
Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97(5):1232-1240. https://doi.org/10.1182/blood.V97.5.1232
Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78(5):1373-1380.
Gratama JW, van Esser JWJ, Lamers CHJ, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 2001;98(5):1358-1364. https://doi.org/10.1182/blood.V98.5.1358
Fernández-Ruiz M, Giménez E, Vinuesa V, et al. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 2019;25(3):381.e1-381.e10. https://doi.org/10.1016/j.cmi.2018.05.010
Bruno F, Fornara C, Zelini P, et al. Follicular helper T-cells and virus-specific antibody response in primary and reactivated human cytomegalovirus infections of the immunocompetent and immunocompromised transplant patients. J Gen Virol. 2016;97(8):1928-1941. https://doi.org/10.1099/jgv.0.000488
Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317(17):1049-1054. https://doi.org/10.1056/NEJM198710223171703
Tian Y, Cox MA, Kahan SM, Ingram JT, Bakshi RK, Zajac AJ. A context-dependent role for IL-21 in modulating the differentiation, distribution, and abundance of effector and memory CD8 T cell subsets. JI. 2016;196(5):2153-2166. https://doi.org/10.4049/jimmunol.1401236
Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009;324(5934):1572-1576. https://doi.org/10.1126/science.1175194
Li L, Liu M, Cheng L-W, et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand J Immunol. 2013;78(5):439-446. https://doi.org/10.1111/sji.12099
Chevalier MF, Julg B, Pyo A, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011;85(2):733-741. https://doi.org/10.1128/JVI.02030-10
van Leeuwen EM, Gamadia LE, Baars PA, Remmerswaal EB, ten Berge IJ, van Lier RA. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J Immunol. 2002;169(10):5838-5843. https://doi.org/10.4049/jimmunol.169.10.5838
He J, Tsai L, Leong Y, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 2013;39(4):770-781. https://doi.org/10.1016/j.immuni.2013.09.007